Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Mason

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
The Journal of Clinical Endocrinology and Metabolism|September 11, 2001
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancerJ C Smith, S Bennett, L M Evans, et al.
Oncogene|January 21, 2014
Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomesJ P Webber, L K Spary, A J Sanders, et al.
Journal of Pediatric Urology|June 11, 2015
Interdisciplinary pain management is beneficial for refractory orchialgia in childrenC B Ching, S R Hays, T R Luckett, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 2, 2008
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trialN D James, M R Sydes, N W Clarke, et al.
Lancet (London, England)|July 26, 2005
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trialR T D Oliver, M D Mason, G M Mead, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 16, 2013
Prostate radiotherapy for men with metastatic disease: a new comparison in the STAMPEDE trialC C Parker, M R Sydes, M D Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2018
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysisC L Vale, D J Fisher, I R White, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trialN W Clarke, A Ali, F C Ingleby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolM R Sydes, M R Spears, M D Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003N W Clarke, A Ali, F C Ingleby, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
The Journal of Clinical Endocrinology and Metabolism|September 11, 2001
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancerJ C Smith, S Bennett, L M Evans, et al.
Oncogene|January 21, 2014
Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomesJ P Webber, L K Spary, A J Sanders, et al.
Journal of Pediatric Urology|June 11, 2015
Interdisciplinary pain management is beneficial for refractory orchialgia in childrenC B Ching, S R Hays, T R Luckett, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 2, 2008
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trialN D James, M R Sydes, N W Clarke, et al.
Lancet (London, England)|July 26, 2005
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trialR T D Oliver, M D Mason, G M Mead, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 16, 2013
Prostate radiotherapy for men with metastatic disease: a new comparison in the STAMPEDE trialC C Parker, M R Sydes, M D Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2018
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysisC L Vale, D J Fisher, I R White, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trialN W Clarke, A Ali, F C Ingleby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolM R Sydes, M R Spears, M D Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003N W Clarke, A Ali, F C Ingleby, et al.
Pageof 9